<DOC>
	<DOCNO>NCT00603759</DOCNO>
	<brief_summary>chemotherapy- radiotherapy-induced oral mucositis represent therapeutic challenge frequently encounter cancer patients.This side effect cause significant morbidity may delay interrupt treatment plan , well reduce therapeutic index . cyclo-oxygenase 2 ( COX-2 ) inducible enzyme primarily express inflamed tissue tumor . COX-2 inhibitor show promise radio- chemosensitizer reduce radio-induced toxicity . conduct phase III , randomize double blind clinical trial evaluate toxicity efficacy celecoxib , selective COX-2 inhibitor , administer concurrently chemotherapy , radiation locally advanced head neck cancer .</brief_summary>
	<brief_title>COX-2 Inhibitor With Concurrent Chemoradiation Locally Advanced Head &amp; Neck Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>stage III/IV ( locally advance ) carcinoma oropharynx , oral cavity , hypopharynx , larynx , nasopharynx primary treatment chemoradiation distant metastasis incomplete treatment adjuvant chemoradiation surgery without apparent tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>COX2 inhibitor</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>chemoradiation</keyword>
</DOC>